Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.76
NYSE:EW's Cash to Debt is ranked lower than
54% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. NYSE:EW: 1.76 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:EW' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 1.06 Max: N/A
Current: 1.76
Equity to Asset 0.61
NYSE:EW's Equity to Asset is ranked lower than
53% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NYSE:EW: 0.61 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:EW' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.6 Max: 0.74
Current: 0.61
0.37
0.74
Interest Coverage 54.54
NYSE:EW's Interest Coverage is ranked lower than
52% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 69.16 vs. NYSE:EW: 54.54 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:EW' s Interest Coverage Range Over the Past 10 Years
Min: 16.5  Med: 63.1 Max: 118.46
Current: 54.54
16.5
118.46
F-Score: 7
Z-Score: 12.60
M-Score: -2.01
WACC vs ROIC
6.19%
32.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 27.04
NYSE:EW's Operating margin (%) is ranked higher than
96% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. NYSE:EW: 27.04 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:EW' s Operating margin (%) Range Over the Past 10 Years
Min: 13.99  Med: 20.5 Max: 53.09
Current: 27.04
13.99
53.09
Net-margin (%) 19.26
NYSE:EW's Net-margin (%) is ranked higher than
92% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 1.24 vs. NYSE:EW: 19.26 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:EW' s Net-margin (%) Range Over the Past 10 Years
Min: 10.36  Med: 15.21 Max: 34.92
Current: 19.26
10.36
34.92
ROE (%) 22.05
NYSE:EW's ROE (%) is ranked higher than
90% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. NYSE:EW: 22.05 )
Ranked among companies with meaningful ROE (%) only.
NYSE:EW' s ROE (%) Range Over the Past 10 Years
Min: 14.26  Med: 19.41 Max: 43.42
Current: 22.05
14.26
43.42
ROA (%) 13.58
NYSE:EW's ROA (%) is ranked higher than
91% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. NYSE:EW: 13.58 )
Ranked among companies with meaningful ROA (%) only.
NYSE:EW' s ROA (%) Range Over the Past 10 Years
Min: 8.72  Med: 12.97 Max: 26.03
Current: 13.58
8.72
26.03
ROC (Joel Greenblatt) (%) 84.30
NYSE:EW's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 4.17 vs. NYSE:EW: 84.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:EW' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 41.35  Med: 53.39 Max: 138.73
Current: 84.3
41.35
138.73
Revenue Growth (3Y)(%) 12.10
NYSE:EW's Revenue Growth (3Y)(%) is ranked higher than
77% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. NYSE:EW: 12.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:EW' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 11.05 Max: 15.1
Current: 12.1
0
15.1
EBITDA Growth (3Y)(%) 19.30
NYSE:EW's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 192 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. NYSE:EW: 19.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:EW' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 17.2 Max: 57.8
Current: 19.3
0
57.8
EPS Growth (3Y)(%) 22.30
NYSE:EW's EPS Growth (3Y)(%) is ranked higher than
75% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. NYSE:EW: 22.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:EW' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 21.8 Max: 288.2
Current: 22.3
0
288.2
» NYSE:EW's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-26)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

EW Guru Trades in Q3 2015

Frank Sands 1,325,385 sh (New)
Louis Moore Bacon 101,319 sh (New)
RS Investment Management 94,785 sh (+36.80%)
Steven Cohen 233,200 sh (+34.64%)
Jim Simons 361,312 sh (+24.50%)
Paul Tudor Jones 4,529 sh (+19.18%)
Pioneer Investments 202,586 sh (+0.38%)
PRIMECAP Management 280,000 sh (unchged)
John Hussman 25,000 sh (unchged)
Steven Cohen 150,000 sh (unchged)
Ray Dalio Sold Out
Lee Ainslie Sold Out
Jeremy Grantham 124,620 sh (-1.93%)
Ron Baron 353,627 sh (-6.81%)
Vanguard Health Care Fund 2,352,060 sh (-30.88%)
Joel Greenblatt 7,777 sh (-92.99%)
» More
Q4 2015

EW Guru Trades in Q4 2015

Frank Sands 10,924,382 sh (+724.24%)
Pioneer Investments 1,578,222 sh (+679.04%)
Jim Simons 1,105,100 sh (+205.86%)
Paul Tudor Jones 9,847 sh (+117.42%)
John Hussman 50,000 sh (+100.00%)
PRIMECAP Management 560,000 sh (+100.00%)
Ron Baron 664,199 sh (+87.82%)
RS Investment Management 168,325 sh (+77.59%)
Jeremy Grantham 215,118 sh (+72.62%)
Vanguard Health Care Fund 3,217,520 sh (+36.80%)
Louis Moore Bacon 120,000 sh (+18.44%)
Steven Cohen 145,400 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen 149,800 sh (-35.76%)
» More
Q1 2016

EW Guru Trades in Q1 2016

Ray Dalio 18,800 sh (New)
Jim Simons 1,665,800 sh (+50.74%)
Pioneer Investments 1,716,295 sh (+8.75%)
RS Investment Management 182,175 sh (+8.23%)
John Hussman 50,000 sh (unchged)
PRIMECAP Management 560,000 sh (unchged)
Louis Moore Bacon Sold Out
Vanguard Health Care Fund Sold Out
Frank Sands 10,172,988 sh (-6.88%)
Ron Baron 528,665 sh (-20.41%)
Jeremy Grantham 149,328 sh (-30.58%)
Paul Tudor Jones 2,600 sh (-73.60%)
Steven Cohen 13,700 sh (-90.85%)
» More
Q2 2016

EW Guru Trades in Q2 2016

Louis Moore Bacon 2,323 sh (New)
Lee Ainslie 32,300 sh (New)
Joel Greenblatt 5,837 sh (New)
Samuel Isaly 175,800 sh (New)
Steven Cohen 194,200 sh (+1317.52%)
Paul Tudor Jones 16,686 sh (+541.77%)
Ray Dalio 33,800 sh (+79.79%)
Jim Simons 2,213,800 sh (+32.90%)
John Hussman 50,000 sh (unchged)
PRIMECAP Management 560,000 sh (unchged)
Jeremy Grantham Sold Out
Pioneer Investments 1,703,864 sh (-0.72%)
Frank Sands 9,619,255 sh (-5.44%)
RS Investment Management 91,090 sh (-50.00%)
Ron Baron 30,903 sh (-94.15%)
» More
» Details

Insider Trades

Latest Guru Trades with EW

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NYSE:ZBH, NAS:ISRG, NYSE:STJ, NYSE:BSX, OTCPK:SNNUF, OTCPK:SONVY, NYSE:VAR, NYSE:TFX, NAS:ALGN, NYSE:SYK, OTCPK:SDMHF, OTCPK:CHEOY, OTCPK:WILLF, NAS:ABMD, OTCPK:FSPKF, OTCPK:EKTAF, NAS:NUVA, OTCPK:GGNDF, NAS:IART, NAS:LIVN » details
Traded in other countries:EWL.Germany, EW.Switzerland,
Edwards Lifesciences Corp technologies that treat structural heart disease and critically ill patients. It manufactures heart valves and repair products used to replace or repair a patient's diseased or defective heart valve.

Edwards Lifesciences Corp was incorporated in Delaware on September 10, 1999. The Company is the manufacturer of heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. It is also a leader in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. It conducts operations all over world and is managed in the following geographical regions: United States, Europe, Japan and Rest of World. The products and technologies provided by the Company to treat cardiovascular disease or critically ill patients are categorized into the following main areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care. The Company's Surgical Heart Valve Therapy portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The portfolio also includes a diverse line of cardiac surgery systems used during minimally invasive surgical procedures, and cannulae, embolic protection devices and other products used during cardiopulmonary bypass. The Company's Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. In the Critical Care portfolio, Edwards Lifesciences' products include pulmonary artery catheters, disposable pressure transducers and monitoring systems. The portfolio also includes a line of balloon catheter-based vascular products, surgical clips and inserts. The Company competes with many companies, including divisions of companies much larger than it and smaller companies that compete in specific product lines or certain geographies. The Company's Surgical Heart Valve Therapy and Transcatheter Heart Valve products are manufactured in California and Utah in the United States, Switzerland, and Singapore. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic. The Company's products and technologies are subject to regulation by numerous domestic and foreign government agencies, including the FDA, and various laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution of its products and technologies.

Ratios

vs
industry
vs
history
P/E(ttm) 50.09
EW's P/E(ttm) is ranked lower than
74% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 27.08 vs. EW: 50.09 )
Ranked among companies with meaningful P/E(ttm) only.
EW' s P/E(ttm) Range Over the Past 10 Years
Min: 11.18  Med: 27.92 Max: 50.58
Current: 50.09
11.18
50.58
Forward P/E 35.59
EW's Forward P/E is ranked lower than
82% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 23.87 vs. EW: 35.59 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 50.09
EW's PE(NRI) is ranked lower than
74% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 27.22 vs. EW: 50.09 )
Ranked among companies with meaningful PE(NRI) only.
EW' s PE(NRI) Range Over the Past 10 Years
Min: 11.16  Med: 27.78 Max: 50.09
Current: 50.09
11.16
50.09
Price/Owner Earnings (ttm) 57.09
EW's Price/Owner Earnings (ttm) is ranked lower than
73% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 31.34 vs. EW: 57.09 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
EW' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.88  Med: 31.41 Max: 572.5
Current: 57.09
7.88
572.5
P/B 10.42
EW's P/B is ranked lower than
91% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. EW: 10.42 )
Ranked among companies with meaningful P/B only.
EW' s P/B Range Over the Past 10 Years
Min: 2.9  Med: 5.16 Max: 10.42
Current: 10.42
2.9
10.42
P/S 9.66
EW's P/S is ranked lower than
82% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 3.23 vs. EW: 9.66 )
Ranked among companies with meaningful P/S only.
EW' s P/S Range Over the Past 10 Years
Min: 2.32  Med: 4.35 Max: 9.66
Current: 9.66
2.32
9.66
PFCF 61.65
EW's PFCF is ranked lower than
82% of the 100 Companies
in the Global Medical Devices industry.

( Industry Median: 30.18 vs. EW: 61.65 )
Ranked among companies with meaningful PFCF only.
EW' s PFCF Range Over the Past 10 Years
Min: 7.83  Med: 35.65 Max: 593.7
Current: 61.65
7.83
593.7
POCF 43.94
EW's POCF is ranked lower than
83% of the 132 Companies
in the Global Medical Devices industry.

( Industry Median: 21.53 vs. EW: 43.94 )
Ranked among companies with meaningful POCF only.
EW' s POCF Range Over the Past 10 Years
Min: 7.34  Med: 21.88 Max: 48.74
Current: 43.94
7.34
48.74
EV-to-EBIT 34.09
EW's EV-to-EBIT is ranked lower than
68% of the 164 Companies
in the Global Medical Devices industry.

( Industry Median: 22.51 vs. EW: 34.09 )
Ranked among companies with meaningful EV-to-EBIT only.
EW' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 20.2 Max: 39.7
Current: 34.09
6.8
39.7
EV-to-EBITDA 31.27
EW's EV-to-EBITDA is ranked lower than
77% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 16.88 vs. EW: 31.27 )
Ranked among companies with meaningful EV-to-EBITDA only.
EW' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4  Med: 15.2 Max: 33.5
Current: 31.27
6.4
33.5
PEG 1.77
EW's PEG is ranked higher than
65% of the 75 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. EW: 1.77 )
Ranked among companies with meaningful PEG only.
EW' s PEG Range Over the Past 10 Years
Min: 0.45  Med: 1.36 Max: 3.46
Current: 1.77
0.45
3.46
Shiller P/E 81.37
EW's Shiller P/E is ranked lower than
74% of the 47 Companies
in the Global Medical Devices industry.

( Industry Median: 42.11 vs. EW: 81.37 )
Ranked among companies with meaningful Shiller P/E only.
EW' s Shiller P/E Range Over the Past 10 Years
Min: 34.67  Med: 63.55 Max: 118.59
Current: 81.37
34.67
118.59
Current Ratio 4.15
EW's Current Ratio is ranked higher than
71% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.56 vs. EW: 4.15 )
Ranked among companies with meaningful Current Ratio only.
EW' s Current Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.66 Max: 5.56
Current: 4.15
0.89
5.56
Quick Ratio 3.38
EW's Quick Ratio is ranked higher than
72% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 1.94 vs. EW: 3.38 )
Ranked among companies with meaningful Quick Ratio only.
EW' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 2.07 Max: 4.83
Current: 3.38
0.49
4.83
Days Inventory 177.06
EW's Days Inventory is ranked lower than
68% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 132.35 vs. EW: 177.06 )
Ranked among companies with meaningful Days Inventory only.
EW' s Days Inventory Range Over the Past 10 Years
Min: 132.4  Med: 169.19 Max: 208.39
Current: 177.06
132.4
208.39
Days Sales Outstanding 56.66
EW's Days Sales Outstanding is ranked higher than
68% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 68.07 vs. EW: 56.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
EW' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.74  Med: 54.46 Max: 69.95
Current: 56.66
38.74
69.95
Days Payable 43.15
EW's Days Payable is ranked lower than
65% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.81 vs. EW: 43.15 )
Ranked among companies with meaningful Days Payable only.
EW' s Days Payable Range Over the Past 10 Years
Min: 33.96  Med: 51.13 Max: 63.34
Current: 43.15
33.96
63.34

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.00
EW's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. EW: 2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EW' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: 0.75 Max: 0
Current: 2
-0.8
0

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 63.80
EW's Price/Net Current Asset Value is ranked lower than
94% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 7.11 vs. EW: 63.80 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EW' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 10.47  Med: 16.9 Max: 568
Current: 63.8
10.47
568
Price/Tangible Book 15.78
EW's Price/Tangible Book is ranked lower than
87% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 4.42 vs. EW: 15.78 )
Ranked among companies with meaningful Price/Tangible Book only.
EW' s Price/Tangible Book Range Over the Past 10 Years
Min: 5.58  Med: 9.61 Max: 199.7
Current: 15.78
5.58
199.7
Price/Projected FCF 3.18
EW's Price/Projected FCF is ranked lower than
66% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. EW: 3.18 )
Ranked among companies with meaningful Price/Projected FCF only.
EW' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.36  Med: 1.94 Max: 3.62
Current: 3.18
1.36
3.62
Price/DCF (Earnings Based) 1.76
EW's Price/DCF (Earnings Based) is ranked higher than
67% of the 18 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. EW: 1.76 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 2.22
EW's Price/Median PS Value is ranked lower than
89% of the 253 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. EW: 2.22 )
Ranked among companies with meaningful Price/Median PS Value only.
EW' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.29  Med: 0.68 Max: 2.22
Current: 2.22
0.29
2.22
Price/Peter Lynch Fair Value 2.00
EW's Price/Peter Lynch Fair Value is ranked lower than
53% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 1.75 vs. EW: 2.00 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
EW' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.59  Med: 1.4 Max: 3.25
Current: 2
0.59
3.25
Price/Graham Number 5.93
EW's Price/Graham Number is ranked lower than
81% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. EW: 5.93 )
Ranked among companies with meaningful Price/Graham Number only.
EW' s Price/Graham Number Range Over the Past 10 Years
Min: 1.81  Med: 3.41 Max: 29.59
Current: 5.93
1.81
29.59
Earnings Yield (Greenblatt) (%) 2.99
EW's Earnings Yield (Greenblatt) (%) is ranked higher than
64% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. EW: 2.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EW' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.5  Med: 5 Max: 14.7
Current: 2.99
2.5
14.7
Forward Rate of Return (Yacktman) (%) 29.46
EW's Forward Rate of Return (Yacktman) (%) is ranked higher than
93% of the 118 Companies
in the Global Medical Devices industry.

( Industry Median: 7.67 vs. EW: 29.46 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
EW' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 6.4  Med: 22.3 Max: 37.4
Current: 29.46
6.4
37.4

More Statistics

Revenue (TTM) (Mil) $2,743
EPS (TTM) $ 2.42
Beta0.62
Short Percentage of Float1.86%
52-Week Range $66.57 - 121.58
Shares Outstanding (Mil)212.88

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 2,981 3,355 3,700 3,814
EPS ($) 2.81 3.38 3.89 4.12
EPS w/o NRI ($) 2.81 3.38 3.89 4.12
EPS Growth Rate
(3Y to 5Y Estimate)
0.85%
Dividends Per Share ($)
» More Articles for NYSE:EW

Headlines

Articles On GuruFocus.com
7 Stocks with Strong Returns and Profitability Aug 04 2016 
Sam Isaly's Top Investments of the Year Aug 01 2016 
Johnson & Johnson Reports 4% Sales Growth for the Second Quarter Jul 22 2016 
Opinions Differ on Abbott Deal to Acquire St. Jude's Medical Jun 18 2016 
Vanguard Sells Out Edwards Lifesciences May 03 2016 
Sands Capital Boosts Stake in Edwards Lifesciences Mar 09 2016 
Frank Sands Acquires Stake in Netflix Feb 23 2016 
15 Best Stocks for Value Investors This Week Feb 15 2016 
Starbucks, Foot Locker Beat the Market Over Past Year Feb 10 2016 
Weekly 52-Week Highs Highlight: H&R Block, Edwards Lifesciences, Amazon.com, Chubb Nov 02 2015 

More From Other Websites
Edwards Lifesciences Leads Healthy Rise For Medical Products Stocks Sep 22 2016
Edwards Lifesciences, DaVita HealthCare Partners, Corcept Therapeutics and CryoLife highlighted as... Sep 22 2016
Bull of the Day: Edwards Lifesciences (EW) Sep 22 2016
Edwards Sapien 3 Transcatheter Heart Valve Receives Expanded Indication In Europe Sep 19 2016
Edwards Sapien 3 Transcatheter Heart Valve Receives Expanded Indication In Europe Sep 19 2016
Zacks.com featured highlights: Sanderson Farms, Edwards Lifesciences, Broadcom Limited, Finisar and... Sep 15 2016
ETF’s with exposure to Edwards Lifesciences Corp. : September 14, 2016 Sep 14 2016
Follow Driehaus Strategy & Invest in These 5 Momentum Stocks Sep 14 2016
Edwards Lifesciences Is Not Missing a Beat Sep 06 2016
Edwards Lifesciences To Present At The 11th Annual Wells Fargo Healthcare Conference Sep 01 2016
How Edwards Lifesciences Trades Compared to Its Peers Sep 01 2016
EW Poised to Carve Out More Prosthetic Heart Valve Market Share Sep 01 2016
Edwards Lifesciences Capitalizes on Valve Replacement Market Aug 31 2016
What Caused Edwards Lifesciences to Guide Higher? Aug 31 2016
Analysts’ Recommendations for Edwards Lifesciences in 2016 Aug 31 2016
Medtronic Misses High Expectations; St. Jude Dives On Hacking Claim Aug 25 2016
Medtronic Earnings Face FX Headwinds, But Cardiac Trends Good Aug 24 2016
Edwards Lifesciences: Rallies on Strong THV Sales, View Up Aug 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)